Effect of Dashboard on performance and validation indicators: absolute and relative intervention effects with 95% CI at 30 months following introduction of intervention, and corresponding time period for external control indicators, 2009–2015
| Clinical performance indicator | Absolute difference from predicted (%) (95% CI for %) | Relative difference from predicted (%) (95% CI for %) |
| Primary analyses | ||
| Indicator 1—unsatisfactory newborn screening samples | 0.40 (−2.17 to 2.97) | 0.17 (−1.85 to 2.20) |
| Indicator 2—episiotomy | −1.51 (−2.39 to −0.64)* | −0.14 (−0.28 to −0.01)* |
| Indicator 3—formula supplementation | 0.30 (−1.01 to 1.08) | 0.00 (−0.07 to 0.07) |
| Indicator 4—elective repeat caesarean delivery prior to 39 weeks | −10.38 (−11.51 to −9.25)* | −0.23 (−0.28 to −0.19)* |
| Indicator 5—GBS screening | 2.84 (2.17 to 3.51)* | 0.03 (0.02 to 0.04)* |
| Indicator 6—postdates induction prior to 41 weeks | −11.69 (−15.96 to −7.42)* | −0.42 (−0.69 to −0.15)* |
| Control analyses | ||
| Internal control outcome 1—caesarean in induced nulliparous women | −0.17 (−1.83 to 1.49) | −0.01 (−0.09 to 0.08) |
| Internal control outcome 2—use of auscultation for fetal surveillance | −2.92 (−8.43 to 2.59) | −0.05 (−0.26 to 0.16) |
| External control indicators (British Columbia data set) | ||
| Indicator 2—episiotomy | 0.78 (0.18 to 1.37)* | 0.18 (−0.11 to 0.48) |
| Indicator 4—elective repeat caesarean delivery prior to 39 weeks | 2.19 (−11.30 to 6.92) | −0.06 (−0.41 to 0.29) |
| Indicator 5—GBS screening | 0.24 (−0.52 to 1.00) | 0.00 (−0.01 to 0.02) |
| Indicator 6—postdates induction prior to 41 weeks | 3.22 (2.49 to 3.96)* | 0.27 (0.13 to 0.42)* |
*P<0.05.
GBS, group B streptococcus.